aXichem AB Class A stock analysis
aXichem AB Class A (A6X) Stock Price & Analysis
A6X Stock Chart & Stats
- Day’s Range
- EUR 0.11 - EUR 0.12
- 52-Week Range
- EUR 0.07 - EUR 0.29
- Previous Close
- EUR 0.11
- Volume
- N/A
- Average Volume (3M)
- 50
- Market Cap
- EUR 11.24M
- Enterprise Value
- EUR 109.16M
- Total Cash (Recent Filing)
- EUR 2.87M
- Total Debt (Recent Filing)
- EUR 595.00K
- Price to Earnings (P/E)
- ―
- Beta
- -0.20
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very modest debt relative to equity reduces near-term solvency pressure and interest burden. This gives aXichem greater financial flexibility than a highly leveraged business, allowing more capacity to pursue regulatory, research, and commercialization activities while losses persist.
Patent-Based Product Platform
A patented phenylcapsaicin platform can support differentiated products and protect intellectual property across animal nutrition and other biological or industrial uses. Multiple potential applications create avenues for licensing, partnerships, and broader commercialization over the next several quarters.
Partner-Led Commercial Model
Using partners and distributors gives aXichem an established route to commercial markets without relying on large-scale in-house manufacturing. This model can help the company focus capital and personnel on R&D, intellectual property, regulatory work, and product adoption.
Bears Say
Revenue Decline And Volatility
The recent revenue contraction and volatile multi-year sales record indicate that commercial demand has not yet become dependable. Continued top-line instability can restrict operating leverage, weaken planning visibility, and make it harder to fund regulatory and product expansion internally.
Deep And Persistent Losses
Negative gross profit and an approximately 95% net margin loss show that the current business model is far from sustainable profitability. Unless pricing, sales scale, or cost economics improve materially, future growth may continue to consume capital rather than build durable earnings.
Recurring Cash Burn
Persistent operating and free-cash-flow deficits reduce financial resilience even though leverage is low. Ongoing cash consumption can require external funding if performance does not improve, potentially limiting strategic flexibility and exposing the company to dilution or financing dependence.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
What is aXichem AB Class A’s market cap?
When is aXichem AB Class A’s upcoming earnings report date?
How were aXichem AB Class A’s earnings last quarter?
Is aXichem AB Class A overvalued?
Does aXichem AB Class A pay dividends?
What is aXichem AB Class A’s EPS estimate?
How many shares outstanding does aXichem AB Class A have?
What happened to aXichem AB Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of aXichem AB Class A?
What is the TipRanks Smart Score and how is it calculated?
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Torsten Helsing
- Employees
- 7
- Website
- axichem.com
- Address
- Södergatan 26, Malmö, SN, 211 34, SE
aXichem AB Class A (A6X) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |





